NCT06063707

Brief Summary

To observe the changes of plasma rTEM levels in patients with sepsis, sepsis induced ARDS, and to explore its clinical significance.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2023

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 31, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2023

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 2, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

October 3, 2023

Status Verified

October 1, 2023

Enrollment Period

10 months

First QC Date

August 31, 2023

Last Update Submit

October 1, 2023

Conditions

Sepsis

Outcome Measures

Primary Outcomes (1)

  • Mortality

    28day mortality

    28 day

Study Arms (2)

Survivors

Sepsis induced ARDS patients who survived

Other: Taking peripheral blood

Nonsurvivors

Sepsis induced ARDS patients who not survived

Other: Taking peripheral blood

Interventions

Taking peripheral bloodOTHER

Taking peripheral blood of no more than 3ml

NonsurvivorsSurvivors

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study enrolled sepsis patients

You may qualify if:

  • Diagnosed as Sepsis 3.0 Patients signing informed consent

You may not qualify if:

  • Pregnant women Patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、HELLP syndrome

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jingyuan Xu, M.D.

    Southeast University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jingyuan Xu, M.D.

CONTACT

00861385141720913851417209@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 31, 2023

First Posted

October 2, 2023

Study Start

October 1, 2023

Primary Completion

August 1, 2024

Study Completion

September 1, 2024

Last Updated

October 3, 2023

Record last verified: 2023-10